Evidence change feed
A dated, sourced record of changes in guideline, regulatory, and payer evidence, mapped to rungs 5–7 of the recognition ladder. Changes are recorded after they occur, never predicted. This is a public record, not a forecast.
Entries are recorded after they occur, newest first, each with a source link, date, and recognition-ladder rung.
AstraZeneca announced an exclusive global license from Dizal for sunvozertinib and confirmed that a supplemental NDA for the first-line EGFR exon 20 insertion indication has been submitted to the US FDA, which granted Breakthrough Therapy Designation in this setting.
Publicly sourced observation of a regulatory transition; observation only, not a forecast.
AstraZenecaNCCN introduced a free Guidelines Weekly Updates email alongside a paid Flash Updates tier, publishing what changed across its guideline library on a fixed cadence.
A public guideline-change delivery pattern now exists; it documents the change flow modeled as rung 5 transitions.
NCCNICER released its annual review of launch prices and access conditions — an independent, conflict-disclosed assessment of how new products enter coverage.
Independent assessments of access conditions are the reference standard for coverage-change records.
ICERFDA published its final guidance describing how firms may communicate truthful, non-misleading scientific information about unapproved uses, including requirements to keep sources unaltered, complete, and conflict-disclosed.
Sets the source-integrity standard that public evidence records are designed to meet.
FDASubscribe for an email when a new entry is added.